Organization | Omrix Biopharmaceuticals, Inc.

Omrix Biopharmaceuticals, Inc. Report issue

Contributed to NME For profit Phase 2 Phase 3

Founded: Qiryat Ono Israel (1995)

Status: Acquired by Johnson and Johnson (2008)

Organization Overview

First Clinical Trial

2004

NCT00196534

First Marketed Drug

2003

thrombin (bovine) (Thrombostat)

First NDA Approval

2007

thrombin (human coagulation factor iia) (Evithrom)

Last Known Activity

2010

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Omrix Biopharmaceuticals | OMRIX Biopharmaceuticals | Omrix Biopharmaceuticals Ltd

Active Ingredients

Marketed Drugs (3)

fibrinogen (human) (RiaSTAP) (2003)

thrombin (bovine) (Thrombostat) (2003)

thrombin (human coagulation factor iia) (Evithrom) (2007 NDA)

Drugs in Phase 3 Trials (6)

cellulose (1 trial)

human fibrin (Tisseel) (5 trials)

immune globulin (human) (Gamastan) (1 trial)

thrombin (2 trials)

thrombin (bovine) (Thrombostat) (1 trial)

thrombin (human coagulation factor iia) (Evithrom) (1 trial)

Drugs in Phase 2 Trials (1)

collagen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Blood Loss, Surgical (Phase 3)

Endometriosis (Phase 3)

Hemorrhage (Phase 3)

Immunologic Deficiency Syndromes (Phase 3)

Ovarian Cysts (Phase 3)

Ovarian Diseases (Phase 2)

Peripheral Arterial Disease (Phase 3)

Peripheral Vascular Diseases (Phase 3)

Syndrome (Phase 3)

Tissue Adhesions (Phase 3)

Vascular Diseases (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 10
# of Trial APIs: 7